CO167 The Incremental Benefit Provided by Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL) When Compared to Real-World Clinical Practice (RWCP)

Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.243
https://www.valueinhealthjournal.com/article/S1098-3015(22)02447-0/fulltext
Section Title :
Section Order : 12048
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02447-0&doi=10.1016/j.jval.2022.09.243
HEOR Topics :
Tags :
Regions :